• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

    10/25/21 7:32:00 AM ET
    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APTX alert in real time by email

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.

    To access the live conference call, please dial (844) 200 6205 (domestic) or (929) 526 1599 (international) and refer to conference ID 322632. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

    About Aptinyx

    Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

    Source: Aptinyx Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005281/en/

    Get the next $APTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APTX

    DatePrice TargetRatingAnalyst
    4/7/2022Outperform → Mkt Perform
    William Blair
    12/20/2021$12.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $APTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khanna Ashish

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:17:54 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Riedel Norbert G

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:17:01 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kidd Andrew

      4 - Aptinyx Inc. (0001674365) (Issuer)

      1/5/23 4:16:09 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

      Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

      4/23/24 8:00:00 AM ET
      $APTX
      $BAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. "Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "His expertise in research and clinical development is amplified by the successful development programs he has overseen across a rang

      10/20/21 7:57:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women's Hospital. "We are delighted to welcome Joan to the Aptinyx Board of Directors," said Norbert Riedel, Ph.D., chief executive offic

      5/10/21 7:57:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aptinyx downgraded by William Blair

      William Blair downgraded Aptinyx from Outperform to Mkt Perform

      4/7/22 1:13:54 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Aptinyx with a new price target

      SVB Leerink reiterated coverage of Aptinyx with a rating of Outperform and set a new price target of $10.00 from $12.00 previously

      12/20/21 4:47:19 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx downgraded by JP Morgan

      JP Morgan downgraded Aptinyx from Neutral to Underweight

      1/29/21 8:18:50 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Financials

    Live finance-specific insights

    See more
    • Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

      Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor

      11/8/22 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'

      10/18/22 7:45:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

       Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the

      8/4/22 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aptinyx Inc. (Amendment)

      SC 13G/A - Aptinyx Inc. (0001674365) (Subject)

      2/9/24 5:16:02 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

      SC 13D/A - Aptinyx Inc. (0001674365) (Subject)

      6/27/23 2:13:31 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aptinyx Inc. (Amendment)

      SC 13D/A - Aptinyx Inc. (0001674365) (Subject)

      3/16/23 4:19:28 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $APTX
    SEC Filings

    See more
    • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

      Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

      4/23/24 8:00:00 AM ET
      $APTX
      $BAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

      Aptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February prior to its completion in support of the company's preservation of capital. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support continued advancement of the development program by Aptinyx. In March, Aptinyx engaged Ladenburg Thalmann as its exclusive fi

      3/30/23 4:05:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

      NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze the data available to date Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-

      2/27/23 4:03:00 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Inc. filed SEC Form 8-K: Other Events

      8-K - Aptinyx Inc. (0001674365) (Filer)

      12/21/23 10:52:00 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptinyx Inc. filed SEC Form 8-K: Other Events

      8-K - Aptinyx Inc. (0001674365) (Filer)

      12/18/23 5:00:17 PM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Aptinyx Inc.

      25-NSE - Aptinyx Inc. (0001674365) (Subject)

      7/10/23 6:04:47 AM ET
      $APTX
      Biotechnology: Pharmaceutical Preparations
      Health Care